Insulin glargine and its place in the treatment of Types 1 and 2 diabetes mellitus

Bibliography

• ZIMMET P, ALBERTI KG, SHAW J: Global and societal implications of the diabetes epidemic. Nature (2001) 414(6865):782-787.
   PubMed Web of Science ®Google Scholar
• DIABETES UK, ALL-PARTY PARLIAMENTARY GROUP, HANSARD SOCIETY: Report: State of the Nations 2005 – Progress made on the national diabetes frameworks (2005).
   Google Scholar
• DEPARTMENT OF HEALTH: Report: National Service Framework for Diabetes. (2001).
   Google Scholar
• DIABETES CONTROL AND COMPLICATIONS TRIAL RESEARCH GROUP: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N. Engl. J. Med. (1993) 329:977-986.
   PubMed Web of Science ®Google Scholar
• WRITING TEAM FOR THE DIABETES CONTROL AND COMPLICATIONS TRIAL/EPIDEMIOLOGY OF DIABETES INTERVENTIONS AND COMPLICATIONS RESEARCH GROUP: Effect of intensive therapy on the microvascular complications of Type 1 diabetes mellitus. JAMA (2002) 287(19):2563-2569.
   Google Scholar
• STRATTON IM, ADLER AI, ANDREW H et al.: Association of glycaemia with macrovascular and microvascular complications of Type 2 diabetes (UKPDS 35): prospective observational study. Br. Med. J. (2000) 321:405-412.
   PubMed Web of Science ®Google Scholar
• UK PROSPECTIVE DIABETES STUDY (UKPDS) GROUP: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with Type 2 diabetes (UKPDS 33). Lancet (1998) 352:837-853.
   PubMed Web of Science ®Google Scholar
• DEPARTMENT OF HEALTH: Report: National Diabetes Audit – key findings about the quality of care for people with diabetes in England (2005).
   Google Scholar
• NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE: Report: clinical guidelines for Type 2 diabetes – management of blood glucose (2002).
   Google Scholar
• BARNETT A: A review of basal insulins. Diabet. Med. (2003) 20:873-885.
   PubMed Web of Science ®Google Scholar
• Diabetes atlas executive summary, 2nd edn. International Diabetes Federation (2003).
   Google Scholar
• CRUICKSHANKS KJ, LAPORTE RE, DORMAN JS et al.: The epidemiology of insulin-dependent diabetes mellitus: etiology and prognosis. In: Coping With Juvenile Diabetes. Ahmed PI, Ahmed N, (Eds). Charles C Thomas, Springfield, IL (1985):332-357.
   Google Scholar
• KARVONEN M, VIIK-KARJANDER M, MOLTCHANOVA E: Incidence of childhood Type 1 diabetes worldwide. Diabetes Care (2000) 23:1516-1526.
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, SINHA K, WEYER C, LOFTAGER M, HIRSCHBERGER S, HEISE T: Time-action profile of the soluble, fatty acid acylated, long-acting insulin analogue NN304. Diabet. Med. (1999) 16:332-338.
   PubMed Web of Science ®Google Scholar
• PIEBER TR, DRAEGER E, KRISTENSEN A, GRILL V: Comparison of three multiple injection regimens for Type 1 diabetes: morning plus dinner or bedtime administration of insulin detemir versus morning plus bedtime NPH insulin. Diabet. Med. (2005) 22:850-857.
   PubMed Web of Science ®Google Scholar
• HEISE T, NOSEK L, RONN BB et al.: Lower within-subject variability of insulin detemir in comparison to nph insulin and insulin glargine in people with Type 1 diabetes. Diabetes (2004) 53:1614-1620.
   PubMed Web of Science ®Google Scholar
• HAAK T, TIENGO A, DRAEGER E, SUNTUM M, WALDHAUSL W: Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with Type 2 diabetes. Diabetes Obes. Metab. (2005) 7:56-64.
   PubMed Web of Science ®Google Scholar
• DE LEEUW I, VAGUE P, SELAM JL et al.: Insulin detemir used in basal-bolus therapy in people with Type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. Diabetes Obes Metab (2005) 7:73-82.
   PubMed Web of Science ®Google Scholar
• STANDL E, LANG H, ROBERTS A: The 12-month efficacy and safety of insulin detemir and NPH insulin in basal-bolus therapy for the treatment of Type 1 diabetes. Diabetes Technol. Ther. (2004) 6:579-588.
   PubMedGoogle Scholar
• VAGUE P, SELAM JL, SKEIE S et al.: Insulin detemir is associated with more predictable glycemic control and reduced risk of hypoglycemia than NPH insulin in patients with Type 1 diabetes on a basal-bolus regimen with premeal insulin aspart. Diabetes Care (2003) 26:590-596.
   PubMed Web of Science ®Google Scholar
• HEINE RJ, VAN GAAL LF, JOHNS D et al.: Exenatide versus insulin glargine in patients with suboptimally controlled Type 2 diabetes. Ann. Intern. Med. (2005) 143:559-569.
   PubMed Web of Science ®Google Scholar
• LEPORE M, PAMPANELLI S, FANELLI C et al.: Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin and Ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes (2000) 49:2142-2148.
   PubMed Web of Science ®Google Scholar
• SCHOLTZ HE, PRETORIUS SG, WESSELS DH, BECKER RH: Pharmacokinetic and glucodynamic variability: assessment of insulin glargine, NPH insulin and insulin ultralente in healthy volunteers using a euglycaemic clamp technique. Diabetologia (2005) 48(10):1988-1995
   PubMed Web of Science ®Google Scholar
• HEINEMANN L, LINKESCHOVA R, RAVE K, HOPESCH B, HEISE T: Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care (2000) 23(5):644-649
   PubMed Web of Science ®Google Scholar
• BERTI L, KELLERER M, BOSSENMAIER B, SEFFER E, SEIPKE G, HARING HU: The long acting human insulin analog HOE 901: characteristics of insulin signalling in comparison to Asp(B10) and regular insulin. Horm. Metab. Res. (1998) 30(3):123-129
   PubMed Web of Science ®Google Scholar
• BAHR M, KOLTER T, SEIPKE G et al.: Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE901) in muscle cells. Eur. J. Pharmacol. (1997) 320:259-265.
   PubMed Web of Science ®Google Scholar
• SEIPKE G, BERCHTHOLD H, GEISEN K et al.: HOE901 – a new insulin with prolonged action. Diabetes (1999) 48(Suppl. 1):25.
   Google Scholar
• COATES PA, MUKHERJEE S, LUZIO S et al.: Pharmacokinetics of a long-acting human insulin analogue (HOE901) in healthy subjects. Diabetes (1995) 44(Suppl. 1):130A.
   Google Scholar
• ROSENSTOCK J, PARK G, ZIMMERMAN J, US INSULIN GLARGINE (HOE): Basal insulin glargine (HOE 901) versus NPH insulin in patients with Type 1 diabetes on multiple daily insulin regimens. US Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group. Diabetes Care (2000) 23:1137-1142.
   PubMed Web of Science ®Google Scholar
• PIEBER TR, EUGENE-JOLCHINE I, DEROBERT E et al.: Efficacy and safety of HOE 901 versus NPH insulin in patients with Type 1 diabetes. Diabetes Care (2000) 23:157-162.
   PubMed Web of Science ®Google Scholar
• RASKIN P, KLAFF L, BERGENSTAL R, HALLE J-P, DONLEY D, MECCA T: A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with Type 1 diabetes. Diabetes Care (2000) 23:1666-1671.
   PubMed Web of Science ®Google Scholar
• RATNER RE, HIRSCH IB, NEIFING JL, GARG SK, MECCA TE, WILSON CA: Less hypoglycaemia with insulin Glargine in intensive insulin therapy for Type 1 diabetes. US study group of insulin Glargine in Type 1 diabetes. Diabetes Care (2000) 23:639-643.
   PubMed Web of Science ®Google Scholar
• ROSSETTI P, PAMPANELLI S, FANELLI C et al.: Intensive replacement of basal insulin in patients with Type 1 diabetes given rapid-acting insulin analog at mealtime. Diabetes Care (2003) 26:1490-1496.
   PubMed Web of Science ®Google Scholar
• PORCELLATI F, ROSSETTI P, PAMPANELLI S et al.: Better long-term glycaemic control with the basal insulin glargine as compared with NPH in patients with Type1 diabetes mellitus given meal-time lispro insulin. Diabet. Med. (2004) 21:1213-1220.
   PubMed Web of Science ®Google Scholar
• MURPHY NP, KEANE SM, ONG KK et al.: Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with Type 1 diabetes on intensive insulin regimens. Diabetes Care (2003) 26:799-804.
   PubMed Web of Science ®Google Scholar
• HOME PD, ROSSKAMP R, FORJANIC-KLAPPROTH J, DRESSLER A: A randomized multicentre trial of insulin glargine compared with NPH insulin in people with Type 1 diabetes. Diabetes Metab. Res. Rev. (2005) 21(6):545-553.
   PubMed Web of Science ®Google Scholar
• FULCHER GR, GILBERT RE, YUE DK: Glargine is superior to neutral protamine Hagedorn for improving glycated haemoglobin and fasting blood glucose levels during intensive insulin therapy. Intern. Med. J. (2005) 35(9):536-542.
   PubMed Web of Science ®Google Scholar
• GARG SK, PAUL JM, KARSTEN JI et al.: Reduced severe hypoglycaemia with insulin glargine in intensively treated adults with Type 1 diabetes. Diabetes Technol. Ther. (2004) 6:589-595.
   Google Scholar
• HAMANN A, MATTHAEI S, ROSAK C et al.: A randomised clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with Type 1 diabetes. Diabetes Care (2003) 26:1738-1744.
   PubMed Web of Science ®Google Scholar
• ASHWELL SG, GEBBIE J, HOME PD: Optimal timing of injection of once-daily insulin glargine in people with Type 1 diabetes using insulin lispro at meal-times. Diabet. Med. (2006) 23:46-52.
   PubMed Web of Science ®Google Scholar
• ALBRIGHT ES, DESMOND R, BELL DS: Efficacy of conversion from bedtime NPH insulin injection to once- or twice-daily injections of insulin glargine in Type 1 diabetic patients using basal/bolus therapy. Diabetes Care (2004) 27:632-633.
   PubMed Web of Science ®Google Scholar
• WITTHAUS E, STEWART J, BRADLEY C: Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with Type 1 diabetes. Diabet. Med. (2001) 18:619-625.
   PubMed Web of Science ®Google Scholar
• TSUI E, BARNIE A, ROSS S, PARKES R, ZINMANN B: Intensive insulin therapy with insulin lispro: a randomized trial of continuous subcutaneous insulin infusion versus multiple daily injection. Diabetes Care (2001) 24:1722-1727.
   Web of Science ®Google Scholar
• HANAIRE-BROUTIN H, MELKI V, BESSIERES-LACOMBE S et al.: Study Group for the Development of Pump Therapy in Diabetes: comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in Type 1 diabetic patients on intensified treatment. Diabetes Care (2000) 23:1232-1235.
   PubMed Web of Science ®Google Scholar
• DEVRIES JH, SNOEK FJ, KONSTENSE PJ et al.: A randomized trial of continuous subcutaneous injection therapy in Type 1 diabetes for patients with long-standing poor glycaemic control. Diabetes Care (2002) 25:2074-2080.
   PubMed Web of Science ®Google Scholar
• HIRSCH IB, BODE BW, GARG S et al.: Continuous subcutaneous insulin infusion (CSII) of insulin aspart versus multiple daily injection of insulin aspart/insulin glargine in Type 1 diabetic patients previously treated with CSII. Diabetes Care (2005) 28:533-538.
   PubMed Web of Science ®Google Scholar
• RIDDLE M: Timely addition of insulin to oral therapy for Type 2 diabetes. Diabetes Care (2002) 25:395-396.
   PubMed Web of Science ®Google Scholar
• LIEBL L, MATA M, ESCHWEGE E: Evaluation of risk factors for the development of complications in Type 2 diabetes in Europe. Diabetologia (2002) 45:S23-S28.
   PubMed Web of Science ®Google Scholar
• MONNIER L, LAPINSKI H, COLETTE C: Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of Type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care (2003) 26:881-885.
   PubMed Web of Science ®Google Scholar
• RIDDLE M, ROSENSTOCK J, GERICH J: The treat-to-target trial: randomised addition of glargine of human NPH insulin to oral therapy of Type 2 diabetic patients. Diabetes Care (2003) 26:3080-3086.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H, KAUPPINEN-MAKELIN R, TIIKKAINEN M et al.: Insulin glargine or NPH combined with metformin in Type 2 diabetes: the LANMET study. Diabetologia (2006) 49:442-451.
   PubMed Web of Science ®Google Scholar
• YKI-JARVINEN H, DRESSLER A, ZIEMAN M, HOE 901/3002 STUDY GROUP: Less nocturnal hypoglycaemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in Type 2 diabetes. HOE 901/3002 Study Group. Diabetes Care (2000) 23:1130-1136.
   PubMed Web of Science ®Google Scholar
• STANDL E, MAXEINER S, RAPTIS S et al.: Good glycaemic control with flexibility in timing of basal insulin supply. Diabetes Care (2005) 28:419-420.
   PubMed Web of Science ®Google Scholar
• GERSTEIN HC, YALE JF, HARRIS SB, ISSA M, STEWART JA, DEMPSEY EA: Randomized trial of early glargine use to achieve optimal a1c levels in insulin naive people with Type 2 diabetes. Diabetes (2005) 54(Suppl. 1):A67-A68 Abstract.
   Google Scholar
• SCHREIBER SA, RUSSMANN A: The effects of insulin glargine treatment and an educational programme on glycaemic control in Type 2 diabetes patients in clinical practice. Curr. Med. Res.Opin. (2006) 22:335-341.
   PubMed Web of Science ®Google Scholar
• JANKA HU, PLEWE G, RIDDLE MC, KLIEBE-FRISCHE C, SCHWEITZER MA, YKI-JARVINEN H: Comparison of basal insulin added to oral agents versus twice-daily premixed insulin as initial insulin therapy for Type 2 diabetes. Diabetes Care (2005) 28:254-259.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, SCHWARTZ SL, CLARK CM et al.: Basal insulin therapy in Type 2 diabetes: 28 week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care (2001) 24:631-636.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, STORMS F, SHUTLER S et al.: Improvement of glycaemic control in subjects with poorly controlled Type 2 diabetes: comparison of two treatment algorithms using insulin glargine. Diabetes Care (2005) 28:1282-1288.
   PubMed Web of Science ®Google Scholar
• RASKIN P, ALLEN E, HOLLANDER P et al.: Initiating insulin therapy in Type 2 diabetes. Diabetes Care (2005) 28:260-265.
   PubMed Web of Science ®Google Scholar
• FONSECA V, BELL DS, BERGER S, THOMSON S, MECCA TE: A comparison of bedtime insulin glargine with bedtime neutral protamine hagedorn insulin in patients with Type 2 diabetes: subgroup analysis of patients taking once-daily insulin in a multicenter, randomized, parallel group study. Am. J. Med. Sci (2004) 328(5):274-280.
   PubMed Web of Science ®Google Scholar
• HERMAN WH, ILAG LL, JOHNSON SL et al.: A clinical trial of continuous subcutaneous insulin infusion versus multiple daily injections in older adults with Type 2 diabetes. Diabetes Care (2005) 28:1568-1573.
   PubMed Web of Science ®Google Scholar
• MASSI BENEDETTI M, HUMBURG E, DRESSLER A, ZIEMEN M: A one year randomised multicentre trial comparing insulin glargine with NPH insulin in combination with oral agents in patients with Type 2 diabetes. Horm. Metab. Res. (2003) 3:189-196.
   Google Scholar
• FRITSCHE A, SCHWEITZER M, HARING HU, THE 4001 STUDY GROUP: Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin or bedtime insulin glargine in patients with Type 2 diabetes: a randomised controlled trial. Ann. Intern. Med. (2003) 138:952-959.
   PubMed Web of Science ®Google Scholar
• ROSENSTOCK J, DAILEY G, MASSI-BENEDETTI M et al.: Reduced hypoglycaemia risk with insulin glargine. Diabetes Care (2005) 28:950-955.
   PubMed Web of Science ®Google Scholar
• BRADLEY C, SPEIGHT J: Patient perceptions of diabetes and diabetes therapy: assessing quality of life. Diabetes Metab. Res Rev (2002) 18(Suppl. 3):S64-S69.
   PubMed Web of Science ®Google Scholar
• WITTHAUS E, STEWART J, BRADLEY C: Improved psychological outcomes after initiation of insulin treatment in patients with Type 2 diabetes. Diabetologia (2000) 43(Suppl. 1):A205.
   Google Scholar
• HOFMANN T, HORSTMANN G, STAMMBERGER I: Evaluation of the reproductive toxicity and embryotoxicity of insulin glargine (LANTUS) in rats and rabbits. Int. J. Toxicol. (2002) 21:181-189.
   PubMed Web of Science ®Google Scholar
• DEVLIN JT, HOTHERSALL L, WILKIS JL: Use of insulin glargine during pregnancy in a Type 1 diabetic woman (Letter). Diabetes Care (2002) 25:1095-1096.
   PubMed Web of Science ®Google Scholar
• HOLSTEIN A, PLASCHKE A, EGBERTS EH: Use of insulin glargine during embryogenesis in a pregnant woman with Type 1 diabetes. Diabet. Med. (2003) 20:779-780.
   PubMed Web of Science ®Google Scholar
• DI CIANNI G, VOLPE L, LENCIONI C et al.: Use of insulin glargine during the first weeks of pregnancy in five Type 1 diabetic women. Diabetes Care. (2005) 4:982-983.
   Google Scholar
• COLINO E, LOPEZ-CAPAPE M, GOLMAYO L, ALVAREZ MA, ALONSO M, BARRIO R: Therapy with insulin glargine (Lantus) in toddlers, children and adolescents with Type 1 diabetes. Diabetes Res. Clin. Pract. (2005) 70(1):1-7.
   PubMed Web of Science ®Google Scholar
• DIXON B, PETER CHASE H, BURDICK J et al.: Use of insulin glargine in children under age 6 with Type 1 diabetes. Pediatr. Diabetes (2005) 6(3):150-154.
   PubMed Web of Science ®Google Scholar
• BOLLI GB, OWENS DR: Insulin glargine. Lancet (2000) 356:443-445.
   PubMed Web of Science ®Google Scholar
• WARREN E, WEATHERLEY-JONES E, CHILCOTT J, BEVERLEY C: Systematic review and economic evaluation of a long-acting insulin analogue, insulin glargine. Health Technol. Assess. (2004) 8(45):1-57.
   Web of Science ®Google Scholar